Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triamcinolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | PGR | P06401 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | CYP2J2 | P51589 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.86 |
| ▸ | AR | P10275 | 2/20 | 0.86 |
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | APEX1 | P27695 | 1/20 | 0.86 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.86 |
| ▸ | IKBKB | O14920 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triamcinolone SCHEMBL1884154 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL9863653 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL601461 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL1502196 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL14373318 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL8813577 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL24622562 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL570639 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL22962813 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL4447 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180235882-A1 | TOPICAL COMPOSITIONS COMPRISING CORTICOSTEROIDS | CADILA HEALTHCARE LIMITED (IN) | 2018-08-23 | — | — | US | claimed |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | claimed |
| EP-1205218-B1 | Topical antipsoriaticum comprising urea, a corticoid and a desinfectant | BENKERT EUGEN GEORG DR MED DEN (DE) | 2004-03-31 | — | — | EP | claimed |
| US-20030060425-A1 | Immune modulation method using steroid compounds | BIOVIE INC. | 2003-03-27 | — | — | US | claimed |
| EP-1205218-A1 | Topical antipsoriaticum comprising urea, a corticoid and a desinfectant | Benkert, Eugen Georg, Dr.med.dent. (DE) | 2002-05-15 | — | — | EP | claimed |
| US-4704358-A | Δ1 -dehydrogenation with heat or air-dried B. cyclooxidans | THE UPJOHN COMPANY (US) | 1987-11-03 | — | — | US | claimed |
| US-4524134-A | BIOCONVERSION WITH ARTHROBACTER SIMPLEX | THE UPJOHN COMPANY (US) | 1985-06-18 | — | — | US | claimed |
| US-4344940-A | DERMATITIS | E. R. SQUIBB & SONS, INC. (US) | 1982-08-17 | — | — | US | claimed |
| US-4011317-A | STEROID DERIVATIVES | RORER ITALIANA S.P.A. (IT) | 1977-03-08 | — | — | US | claimed |
| CN-118019750-A | Drug delivery system for local delivery of therapeutic agents and uses thereof | 上海椿安生物医药科技有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-11913031-B2 | Method to reproduce circadian rhythms on a microfluidic chip | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-02-27 | — | — | US | disclosed |
| EP-3013407-B1 | MEDICAL TREATMENT SYSTEM | VAPOROX INC (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-4260844-A1 | OPHTHALMOLOGICAL COMPOSITIONS COMPRISING POLOXAMER | Liegner, Jeffery T. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-11744961-B2 | Portable medical treatment system and method of use | VAPOROX, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-4086254-A | ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1978-04-25 | — | — | US | disclosed |
| US-4057469-A | Process for the microbiological oxidation of steroids | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1977-11-08 | — | — | US | disclosed |
| US-4051241-A | ANTIALLERGIC AGENTS, ANTIRHEUMATIC AGENTS, DERMATOLOGIC DRUGS ION | SYNTEX (U.S.A.) INC. (US) | 1977-09-27 | — | — | US | disclosed |
| US-4017615-A | ESPECIALLY USEFUL FOR ANTIINFLAMMATORY TOPICAL CORTICOIDS | SYNTEX CORPORATION (PM) | 1977-04-12 | — | — | US | disclosed |
| US-3984544-A | Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor | SCHERING CORPORATION (US) | 1976-10-05 | — | — | US | disclosed |
| US-3971772-A | ANTINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060425-A1 | Immune modulation method using steroid compounds | HSD3B1, NR5A1, HSD17B1 | NR3C1 15/4885HIF1A 724/4885CYP3A4 126/4885 |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | RECQL, GSS, DDX17 | NR3C1 104/4885HIF1A 1076/4885CYP3A4 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.